The rLVS (Delta) capB/ iglABC vaccine provides potent protection in Fischer rats against inhalational tularemia caused by various virulent Francisella tularensis strains

By sjmartinez • November 18, 2023

Mlynek KD, Cline CR, Biryukov SS, Toothman RG, Bachert BA, Klimko CP, Shoe JL, Hunter M, Hedrick ZM, Dankmeyer JL, Mou S, Fetterer DP, Qiu J, Lee ED, Cote CK, Jia Q, Horwitz MA, Bozue JA. The rLVS ΔcapB/iglABC vaccine provides potent protection in Fischer rats against inhalational tularemia caused by various virulent Francisella tularensis strains. Hum Vaccin Immunother. 2023 Dec 15;19(3):2277083. doi: 10.1080/21645515.2023.2277083. Epub 2023 Nov 17. PMID: 37975637.

Tags: aerosol challenge, animal model, Francisella tularensis, Infectious Diseases, Live Vaccine Strain, LVS, Publications, rat, tularemia, vaccines

Related Posts

Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to[...]

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]

Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative

Wohl DA, Adam SJ, Gibbs KW, Moskowitz AL, Ortel TL, Singh U, Jilg N, Evering TH, Fischer WA 2nd, Taiwo BO, Daar ES, Lindsell CJ,[...]